212 related articles for article (PubMed ID: 25263162)
1. MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma.
Huang CT; Oyang YJ; Huang HC; Juan HF
Sci Rep; 2014 Sep; 4():6495. PubMed ID: 25263162
[TBL] [Abstract][Full Text] [Related]
2. Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer.
Zhao Y; Wang H; Wu C; Yan M; Wu H; Wang J; Yang X; Shao Q
Oncol Rep; 2018 Mar; 39(3):1197-1206. PubMed ID: 29328463
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
4. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma.
Liu X; He M; Hou Y; Liang B; Zhao L; Ma S; Yu Y; Liu X
Oncol Rep; 2013 Apr; 29(4):1415-20. PubMed ID: 23380809
[TBL] [Abstract][Full Text] [Related]
6. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
[TBL] [Abstract][Full Text] [Related]
7. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
Geraldo MV; Kimura ET
PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression profiles in the management of papillary thyroid cancer.
Lee JC; Gundara JS; Glover A; Serpell J; Sidhu SB
Oncologist; 2014 Nov; 19(11):1141-7. PubMed ID: 25323484
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
11. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-based molecular classification of papillary thyroid carcinoma.
Rosignolo F; Memeo L; Monzani F; Colarossi C; Pecce V; Verrienti A; Durante C; Grani G; Lamartina L; Forte S; Martinetti D; Giuffrida D; Russo D; Basolo F; Filetti S; Sponziello M
Int J Oncol; 2017 May; 50(5):1767-1777. PubMed ID: 28393181
[TBL] [Abstract][Full Text] [Related]
13. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
14. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
15. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
17. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma.
Zhang J; Liu Y; Liu Z; Wang XM; Yin DT; Zheng LL; Zhang DY; Lu XB
Int J Med Sci; 2013; 10(5):585-92. PubMed ID: 23533107
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Identification of Potential Crucial Genes and miRNA-mRNA Regulatory Networks in Papillary Thyroid Cancer.
Nan BY; Xiong GF; Zhao ZR; Gu X; Huang XS
Biomed Res Int; 2021; 2021():6752141. PubMed ID: 33521130
[TBL] [Abstract][Full Text] [Related]
19. Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.
Graham ME; Hart RD; Douglas S; Makki FM; Pinto D; Butler AL; Bullock M; Rigby MH; Trites JR; Taylor SM; Singh R
J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):33. PubMed ID: 26341226
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
